Page last updated: 2024-11-11

4-(2-hydroxy-3-(n-isopropylamino)propoxyimino)carane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-(2-hydroxy-3-(N-isopropylamino)propoxyimino)carane: structure given in first source; RN given refers to the (1R-(1alpha,3E(R*),4beta,6alpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9576915
MeSH IDM0212292

Synonyms (6)

Synonym
bicyclo(4.1.0)heptan-3-one, 4,7,7-trimethyl-, o-(2-hydroxy-3-((1-methylethyl)amino)propyl)oxime, (1r-(1alpha,3e(r*),4beta,6alpha))-
4-(2-hydroxy-3-(n-isopropylamino)propoxyimino)carane
145841-19-6
hipi-cis-carane
1-(propan-2-ylamino)-3-[(e)-[(1r,4r,6s)-4,7,7-trimethyl-3-bicyclo[4.1.0]heptanylidene]amino]oxypropan-2-ol
1-(propan-2-ylamino)-3-[(4,7,7-trimethyl-3-bicyclo[4.1.0]heptanylidene)amino]oxypropan-2-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]